Brief: VBI Vaccines Announces Initiation Of Phase 1 Study Of Multivalent Coronavirus Vaccine Candidate, VBI-2901
29/09/2022 13:21
Sept 29 (Reuters) - VBI Vaccines Inc VBIV.O :
* VBI VACCINES ANNOUNCES INITIATION OF PHASE 1 STUDY OF
MULTIVALENT CORONAVIRUS VACCINE CANDIDATE, VBI-2901
* VBI VACCINES INC - INTERIM DATA EXPECTED MID-YEAR 2023,
SUBJECT
TO SPEED OF ENROLLMENT
* VBI VACCINES INC - STUDY IS SUPPORTED BY FUNDING FROM
GOVERNMENT
OF CANADA'S ISED THROUGH STRATEGIC INNOVATION FUND
Source text for Eikon: ID:nBw7VTdtKa
Further company coverage: VBIV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on VBI Vaccines
See all newsBrief: VBI Vaccines Provides Update On Its Restructuring Proceedings
Brief: Vbi Vaccines Announces New Tumor Response Data From Ongoing Randomized Controlled Phase 2B Study Of Vbi-1901 In Recurrent Glioblastoma Patients
VBI Vaccines Inc reports results for the quarter ended in March - Earnings Summary
Brief: VBI Vaccines Says Entered At Market Offering Deal For Gross Proceeds Of Up To $8.5 Mln
Brief: VBI Vaccines Q1 Adjusted EPS USD -0.55